MATINAS BIOPHARMA HOLDINGS I (MTNB)

Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 32 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. The company is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. The company is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.

Company Info

MATINAS BIOPHARMA HOLDINGS I

Suite 302, 1545 Route 206 South

Bedminster NEW JERSEY 07921

P: 19084431860

CEO: Jerome D. Jabbour

Employees: 32

Website: https://www.matinasbiopharma.com/